Alabama-Clinical Trials Unit

阿拉巴马州临床试验单位

基本信息

  • 批准号:
    8116816
  • 负责人:
  • 金额:
    $ 51.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-08-02 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Despite the tremendous progress in the treatment and prevention of HIV infection in the United States there remain significant deficiencies in care and prevention. Antiretroviral therapy failure occurs, unexpected toxicities have emerged, long-term secondary complications have arisen, mother-to-child transmission still befalls mothers and infants in resource poor settings, and the rate of infection continues unabated. The Southeastern United States has the fastest rising number of new HIV infections in the U.S., particularly among African American women. This places Alabama and the University of Alabama Birmingham (UAB) in the heart of this growing epidemic that disproportionately afflicts the most vulnerable populations. This is confounded by the fact that an estimated 50% of infected individuals in this region are unaware they are carrying the virus. The UAB Center for AIDS Research (CFAR) has been at the forefront of HIV prevention and therapeutic investigation for over 18 years. The UAB CFAR is committed to providing the most modern, up to date, therapeutic and prevention interventions to patients and at-risk populations in our State. In response to the NIAID's call for site applications to perform clinical studies that address the emerging issues in HIV treatment and prevention, the UAB CFAR has formed the Alabama-Clinical Trials Unit (A-CTU): A partnership of UAB investigators dedicated to the conduct of high-impact HIV-related studies in a resource poor region of the United States. The A-CTU is comprised of an efficient Central Administration and four Clinical Research Sites (CRS): Alabama Therapeutics-CRS (AT-CRS), The Alabama Vaccine-CRS (AV-CRS), The Alabama Pediatric, Adolescent & Maternal-CRS (APAM-CRS), and The Alabama Microbicide-CRS (AM-CRS). The A-CTU draws on tremendous experience and success in NIAID-sponsored research trials groups, including over 13 years of involvement in the Adult and Pediatric AIDS Clinical Trials Group (AACTG; PACTG), 12 years experience in the HIV Prevention Trials Network (HPTN), and 11 years of continuous involvement as a federally funded HIV vaccine trials site under the AIDS Vaccine Evaluation Group and the HIV Vaccine Trials Network. Owing to this wealth of experience, we are submitting this single coordinated CTU application in response to 5 of the 6 High-Profile Targeted Areas of Investigation: Vaccine research, translational and drug development research, optimization of clinical management research (including comorbidities), microbicide research, and prevention of mother-to-child transmission research. Addressing these Priority Areas will be accomplished through utilization of the A-CTU's genuine partnership with the patient/participant community, its experience in NIAID and industry-funded clinical trials, and through collaborative research among clinical and basic science investigators within the UAB CFAR. ADMINISTRATIVE COMPONENT:
描述(由申请人提供):尽管美国在艾滋病毒感染的治疗和预防方面取得了巨大进展,但在护理和预防方面仍存在重大缺陷。抗逆转录病毒治疗失败时有发生,出现了意想不到的毒性,出现了长期的继发性并发症,在资源贫乏的环境中,母婴传播仍然发生在母亲和婴儿身上,感染率继续有增无减。美国东南部是美国新增艾滋病毒感染人数增长最快的地区,尤其是非洲裔美国妇女。这使得阿拉巴马州和阿拉巴马大学伯明翰分校(UAB)处于这种日益严重的流行病的中心,这种流行病不成比例地折磨着最脆弱的人群。令人困惑的是,该地区估计有50%的感染者不知道自己携带了病毒。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael S. Saag其他文献

Impact of Depression and HIV Symptoms on Glycemic Outcomes among Patients with HIV and Type 2 Diabetes: A Clinical Cohort Study
  • DOI:
    10.1007/s10461-025-04653-7
  • 发表时间:
    2025-02-17
  • 期刊:
  • 影响因子:
    2.400
  • 作者:
    Veronica Joyce Brady;Amanda L. Willig;Katerina A. Christopoulos;David J. Grelotti;George A. Yendewa;Conall O’Cleirigh;Richard D. Moore;Sonia Napravnik;Allison Webel;Heidi M. Crane;Michael S. Saag;Stephanie A Ruderman
  • 通讯作者:
    Stephanie A Ruderman
Treatment of Histoplasmosis and Blastomycosis
  • DOI:
    10.1378/chest.93.4.848
  • 发表时间:
    1988-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Michael S. Saag;William E. Dismukes
  • 通讯作者:
    William E. Dismukes
Correction: Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time Among People with HIV in the Current Treatment Era
  • DOI:
    10.1007/s10461-024-04566-x
  • 发表时间:
    2024-12-03
  • 期刊:
  • 影响因子:
    2.400
  • 作者:
    Jimmy Ma;Joseph A. C. Delaney;Stephanie A. Ruderman;Robin M. Nance;Andrew W. Hahn;Lydia N. Drumright;Bridget M. Whitney;Rob J. Fredericksen;L. Sarah Mixson;Joseph O. Merrill;Steven A. Safren;Kenneth H. Mayer;Conall O’Cleirigh;Sonia Napravnik;Geetanjali Chander;Richard D. Moore;Katerina A. Christopoulos;Amanda L. Willig;Laura Bamford;Allison Webel;Mary E. McCaul;Edward R. Cachay;Jeffrey M. Jacobson;Michael S. Saag;Mari M. Kitahata;Heidi M. Crane;Emily C. Williams
  • 通讯作者:
    Emily C. Williams
Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV
在对 HIV 的初次免疫应答期间,具有主要 Vβ 使用情况的 CD8+T 细胞的主要扩增
  • DOI:
    10.1038/370463a0
  • 发表时间:
    1994-08-11
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Giuseppe Pantaleo;James F. Demarest;Hugo Soudeyns;Cecilia Graziosi;François Denis;Joseph W. Adelsberger;Persephone Borrow;Michael S. Saag;George M. Shaw;Rafick P. Sekalytt;Anthony S. Fauci
  • 通讯作者:
    Anthony S. Fauci
Correction to: Genetic architecture of cardiometabolic risks in people living with HIV
对“HIV 感染者心脏代谢风险的遗传结构”的更正
  • DOI:
    10.1186/s12916-021-01976-9
  • 发表时间:
    2021-05-05
  • 期刊:
  • 影响因子:
    8.300
  • 作者:
    Haoxiang Cheng;Anshuman Sewda;Carla Marquez-Luna;Sierra R. White;Bridget M. Whitney;Jessica Williams-Nguyen;Robin M. Nance;Won Jun Lee;Mari M. Kitahata;Michael S. Saag;Amanda Willig;Joseph J. Eron;W. Christopher Mathews;Peter W. Hunt;Richard D. Moore;Allison Webel;Kenneth H. Mayer;Joseph A. Delaney;Paul K. Crane;Heidi M. Crane;Ke Hao;Inga Peter
  • 通讯作者:
    Inga Peter

Michael S. Saag的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael S. Saag', 18)}}的其他基金

INCIDENCE, PREDICTORS, AND CLINICAL OUTCOMES OF SARS-CoV-2 INFECTION IN PERSONS WITH HIV
HIV 感染者感染 SARS-CoV-2 的发病率、预测因素和临床结果
  • 批准号:
    10305900
  • 财政年份:
    2021
  • 资助金额:
    $ 51.82万
  • 项目类别:
UAB-MISS WIHS Cohort
UAB-MISS WIHS 队列
  • 批准号:
    8432693
  • 财政年份:
    2013
  • 资助金额:
    $ 51.82万
  • 项目类别:
Integration of Evidence-based Alcohol Interventions into HIV Care
将循证酒精干预措施纳入艾滋病毒护理
  • 批准号:
    8330815
  • 财政年份:
    2011
  • 资助金额:
    $ 51.82万
  • 项目类别:
Integration of Evidence-based Alcohol Interventions into HIV Care
将循证酒精干预措施纳入艾滋病毒护理
  • 批准号:
    8529402
  • 财政年份:
    2011
  • 资助金额:
    $ 51.82万
  • 项目类别:
Integration of Evidence-based Alcohol Interventions into HIV Care
将循证酒精干预措施纳入艾滋病毒护理
  • 批准号:
    8720633
  • 财政年份:
    2011
  • 资助金额:
    $ 51.82万
  • 项目类别:
Integration of Evidence-based Alcohol Interventions into HIV Care
将循证酒精干预措施纳入艾滋病毒护理
  • 批准号:
    8211871
  • 财政年份:
    2011
  • 资助金额:
    $ 51.82万
  • 项目类别:
Alabama-Clinical Trials Unit
阿拉巴马州临床试验单位
  • 批准号:
    8145929
  • 财政年份:
    2010
  • 资助金额:
    $ 51.82万
  • 项目类别:
UAB Center for AIDS Research
阿拉巴马大学艾滋病研究中心
  • 批准号:
    8110793
  • 财政年份:
    2010
  • 资助金额:
    $ 51.82万
  • 项目类别:
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS
CNICS 综合临床科学 CFAR 网络主动提供的 R24
  • 批准号:
    8121744
  • 财政年份:
    2010
  • 资助金额:
    $ 51.82万
  • 项目类别:
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS
CNICS 综合临床科学 CFAR 网络主动提供的 R24
  • 批准号:
    7926709
  • 财政年份:
    2009
  • 资助金额:
    $ 51.82万
  • 项目类别:

相似海外基金

AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    10306319
  • 财政年份:
    2014
  • 资助金额:
    $ 51.82万
  • 项目类别:
AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    9984198
  • 财政年份:
    2014
  • 资助金额:
    $ 51.82万
  • 项目类别:
AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    10527322
  • 财政年份:
    2014
  • 资助金额:
    $ 51.82万
  • 项目类别:
AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    10747032
  • 财政年份:
    2014
  • 资助金额:
    $ 51.82万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
  • 批准号:
    7718385
  • 财政年份:
    2008
  • 资助金额:
    $ 51.82万
  • 项目类别:
PEDIATRIC LATE OUTCOMES (AIDS CLINICAL TRIAL GROUP # 219)
儿科晚期结果(艾滋病临床试验组
  • 批准号:
    7603425
  • 财政年份:
    2007
  • 资助金额:
    $ 51.82万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
  • 批准号:
    7605681
  • 财政年份:
    2007
  • 资助金额:
    $ 51.82万
  • 项目类别:
PACTG(PEDIATRIC AIDS CLINICAL TRIAL GROUP) 1058 : PHARMACOKINETIC STUDIES
PACTG(儿科艾滋病临床试验组)1058:药代动力学研究
  • 批准号:
    7603580
  • 财政年份:
    2007
  • 资助金额:
    $ 51.82万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
  • 批准号:
    7378240
  • 财政年份:
    2006
  • 资助金额:
    $ 51.82万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -
成人艾滋病临床试验组纵向连锁随机试验 (ALLRT) -
  • 批准号:
    7606380
  • 财政年份:
    2006
  • 资助金额:
    $ 51.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了